Actelion Pharmaceuticals
Australia Pty Ltd has announced
that Opsumit (macitentan), a new
endothelin receptor antagonist
(ERA) for the treatment of
pulmonary arterial hypertension
(PAH) is available on the
Pharmaceutical Benefits Scheme
(PBS) effective 01 Sep.
Opsumit is indicated for PAH
under specific conditions as either
monotherapy or in combinations
with other approved therapies.The above article was sent to subscribers in Pharmacy Daily's issue from 03 Sep 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 03 Sep 14
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.